Current Pharmaceutical Design

Author(s): Dmitry I. Osolodkin, Vladimir A. Palyulin, Nikolay S. Zefirov

DOI: 10.2174/1381612811306040665

Glycogen Synthase Kinase 3 as an Anticancer Drug Target: Novel Experimental Findings and Trends in the Design of Inhibitors

Page: [665 - 679] Pages: 15

  • * (Excluding Mailing and Handling)

Abstract

Glycogen synthase kinase 3 (GSK-3) is a ubiquitous serine/threonine protein kinase participating in numerous pathways. Very important among them are cancer-related pathways, such as Wnt pathway and nuclear factor κB pathway. The recent findings concerning possible applicability of GSK-3 inhibitors as anticancer agents are summarized in this review, and controversies in the data are highlighted. The most actual concepts of GSK-3 inhibitor design are also thoroughly discussed.

Keywords: Glycogen synthase kinase 3, molecular design, cancer treatment, kinase inhibitors, Wnt pathway